Drew Provan, BSc, MBChB, MD, FRCP, FRCPath, Queen Mary University of London, London, UK, discusses unmet needs in immune thrombocytopenia (ITP), including the need for diagnostic tests, biomarkers to assess risk, and novel agents to improve treatment options for patients. This interview took place at the XIII Eurasian Hematology-Oncology Congress (EHOC) held in Istanbul, Turkey.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.